Grafton Therapeutics Sarl has identified halogenated somatostatin analogues acting as somatostatin SST2 receptor and/or SST5 receptor agonists reported to be useful for the treatment of cancer.

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and neurodegeneration.

Researchers at Jinan Chengcheng Biotechnology Co. Ltd. and Shandong University have disclosed compounds acting as hypoxia-inducible factor 2-α (HIF-2α; EPAS1) activators and vaccine adjuvant reported to be useful for the treatment of stroke, hypertension, chronic kidney disease and more.

Deciphera Pharmaceuticals LLC has described serine/threonine-protein kinase ULK1 and/or ULK2 and/or leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer.

Genescience Pharmaceuticals Co. Ltd. has divulged MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of rheumatoid arthritis and radiographic axial spondyloarthritis (ankylosing spondylitis).

Scientists from Abbvie Deutschland GmbH & Co. KG and Abbvie Inc. have identified radiolabeled compounds capable of imaging and targeting microtubule-associated protein Tau (PHF-tau; MAPT) aggregates acting as positron emission tomography (PET) imaging agents reported to be useful for the diagnosis of progressive supranuclear palsy.

Acurex Biosciences Corp. has synthesized phenothiazines acting as ferroptosis inhibitors reported to be useful for the treatment of mitochondrial disease.

Japan Tobacco Inc. has disclosed pyrazolopyrimidine compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, inflammatory bowel disease and more.

Auron Therapeutics Inc. has described proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a histone acetyltransferase KAT2A and/or KAT2B (PCAF)-targeting moiety through a linker.

Artivila Biopharma has divulged azepine fused ring compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of coronary heart disease, inflammatory bowel disease, liver diseases, myocardial infarction, neurodegeneration, stroke, inflammatory disorders and renal disorders, among others.